|
Report No. : |
344322 |
|
Report Date : |
08.10.2015 |
IDENTIFICATION DETAILS
|
Name : |
SK BIOTEK CO., LTD. |
|
|
|
|
Registered Office : |
325,
Expo-ro, Yuseong-gu, Daejeon, Korea, 34124 |
|
|
|
|
Country : |
South
Korea |
|
|
|
|
Date of Incorporation : |
01.04.2015 |
|
|
|
|
Com. Reg. No.: |
208-81-28353 |
|
|
|
|
Legal Form : |
Co., Ltd By Shares |
|
|
|
|
Line of Business : |
Manufacture and Wholesales of Pharmaceuticals,
Raw Materials, Medical Devices & Supplies |
|
|
|
|
No. of Employees : |
Not Available |
RATING & COMMENTS
|
MIRA’s Rating : |
NB |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
|
-- |
NB |
New Business |
-- |
|
|
Status : |
New Business |
|
Payment Behaviour : |
Unknown |
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31, 2015
|
Country Name |
Previous Rating (31.12.2014) |
Current Rating (31.03.2015) |
|
South Korea |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
SOUTH KOREA - ECONOMIC OVERVIEW
South Korea over the past four decades has demonstrated
incredible economic growth and global integration to become a high-tech industrialized
economy. In the 1960s, GDP per capita was comparable with levels in the poorer
countries of Africa and Asia. In 2004, South Korea joined the trillion-dollar
club of world economies. A system of close government and business ties,
including directed credit and import restrictions, initially made this success
possible. The government promoted the import of raw materials and technology at
the expense of consumer goods, and encouraged savings and investment over
consumption. The Asian financial crisis of 1997-98 exposed longstanding
weaknesses in South Korea's development model, including high debt/equity
ratios and massive short-term foreign borrowing. GDP plunged by 7% in 1998, and
then recovered by 9% in 1999-2000. South Korea adopted numerous economic
reforms following the crisis, including greater openness to foreign investment
and imports. Growth moderated to about 4% annually between 2003 and 2007. South
Korea's export focused economy was hit hard by the 2008 global economic
downturn, but quickly rebounded in subsequent years, reaching over 6% growth in
2010. The US-Korea Free Trade Agreement was ratified by both governments in
2011 and went into effect in March 2012. Between 2012 and 2014, the economy
experienced slow growth due to sluggish domestic consumption and investment.
The administration in 2015 is likely to face the challenge of balancing heavy
reliance on exports with developing domestic-oriented sectors, such as
services. The South Korean economy's long-term challenges include a rapidly
aging population, inflexible labor market, dominance of large conglomerates
(chaebols), and the heavy reliance on exports, which comprise about half of
GDP. In an effort to address the long term challenges and sustain economic
growth, the current government has prioritized structural reforms,
deregulation, promotion of entrepreneurship and creative industries, and the
competitiveness of small and medium enterprises.
|
Source
: CIA |
|
Company Name |
SK BIOTEK CO., LTD. (Korean Company Name : “에스케이바이오텍(주)”) |
|
Registered Address |
325,
Expo-ro, Yuseong-gu, Daejeon, Korea |
|
Building |
|
|
Zip Code |
34124 |
|
Tel |
+82-42-866-7505 |
|
Fax |
+82-42-866-7789 |
|
E-mail |
|
|
Website |
www.skbiotek.com |
|
Trading Address |
325, Expo-ro, Yuseong-gu, Daejeon, Korea (Old Address System : 140-1, Wonchon-dong,
Yuseong-gu, Daejeon, Korea) |
|
Tel |
+82-42-866-7505 |
|
Fax |
+82-42-866-7789 |
|
Other Address |
|
|
Tel |
|
|
Fax |
|
|
Type |
Export/Import |
|
Industry |
Manufacture and Wholesales of
Pharmaceuticals, Raw Materials, Medical Devices & Supplies |
|
Main Business |
Pharmaceuticals & Bio Science Related
R&D, Development and Investment, Market Research, Consulting, Environment
Related Business |
|
Sub
Business |
|
|
Established (mm/dd/yyyy) |
04/01/2015 |
|
Activity |
Detailed Products (UNSPSC) |
|
Sell |
Drugs and Pharmaceutical Products(51000000) |
|
Sell |
Biochemicals(12352200) |
|
Sell |
Chemistry reagents or solutions(41116105) |
|
Sell |
Formulas and products for nutritional support(42231800) |
|
Name |
Park Joon-Ku |
|
Address |
Suite 113-401, 196, Gangsong-ro,
Ilsandong-gu, Goyang-si, Gyeonggi-do, Korea |
|
Date of Birth |
01/10/1961 |
|
Title |
President & CEO |
|
Sex |
Male |
|
Nationality |
Korean |
|
Capital (KRW) |
10,000,000,000 |
|||||||||
|
Employees |
N/A |
|||||||||
|
Formation |
Co., Ltd by Shares A Company of SK Group |
|||||||||
|
Bank Details |
Shinhan Bank KEB Hana Bank |
|||||||||
|
Corporate Registered No. |
160111-0395453 |
|||||||||
|
Business Registered No. |
208-81-28353 |
|||||||||
|
Permit & Licenses |
N/A |
|||||||||
|
Shareholder Position |
|
|||||||||
|
Company History |
04/01/2015 Incorporated as the present name
after split off from SK BIOPHARMACEUTICALS CO., LTD.(110111-4570720) |
|||||||||
|
|
|
Management
|
Job Description |
Title |
Name |
Sex |
Nationality |
Inauguration Date |
|
President & CEO |
Mr. |
Park Joon-Ku |
Male |
Korean |
04/01/2015 |
|
Director |
Mr. |
Cho Jung-Woo |
Male |
Korean |
04/01/2015 |
|
Director |
Mr. |
Yoon Ik-Sang |
Male |
Korean |
04/01/2015 |
|
Auditor |
Mr. |
Kang Chang-Kyun |
Male |
Korean |
04/01/2015 |
Financial Description
|
Authorized Capital(KRW) |
80,000,000,000 |
|
Paid-Up Capital(KRW) |
10,000,000,000 |
|
Total Issued Shares |
20,000,000 |
|
Main Products & Services |
Pharmaceuticals & Bio Science Related
R&D, Development and Investment, Market Research, Consulting, Environment
Related Business |
|
Detailed Products Spec. |
|
|
Technologies Acquired |
|
|
Suppliers |
|
|
Customers |
|
|
Competitors |
DAEWOONG BIO INC. HYANGNAM PHARMACEUTICAL INDUSTRIES COMPLEX,
35-9, JEYAKGONGDAN 4-GIL, HYANGNAM-EUP, HWASEONG-SI, GYEONGGI-DO, KOREA TEL:+82-31-353-5271~3 FAX:+82-31-353-5626 KOREA BIO-CHEM PHARMACEUTICAL INC. 204, SANDAN-GIL, JEONUI-MYEON, SEJONG-SI, KOREA TEL:+82-41-8650-5030 FAX:+82-41-8650-0057 LG LIFE SCIENCES LTD. LG KWANGWHAMUN BLDG., 58, SAEMUNAN-RO,
JONGNO-GU, SEOUL, KOREA TEL:+82-2-3773-1114 FAX:+82-2-3773-7012 |
|
Affiliates |
SK BIOPHARMACEUTICALS CO., LTD.(110111-4570720) SK HOLDINGS CO., LTD.(110111-0769583) SK LIFE SCIENCE, INC. SK INNOVATION CO., LTD.(110111-3710385) SK ENERGY CO., LTD.(110111-4505967) SK GLOBAL CHEMICAL CO., LTD.(110111-4505975) SK TELECOM CO., LTD.(110111-0371346) SK C&C CO., LTD.(110111-0769583) SK TELINK, CORP.(110111-1533599) INNOACE CO., LTD(110111-2104026) PAXNET, INC.(110111-1698830) IHQ, INC.(110111-0042393) AIRCROSS CO., LTD.(110111-2121765) TU MEDIA CORPORATION(110111-2907826) SK COMMUNICATIONS CO., LTD.(110111-1322885) COMMERCE PLANET CO., LTD.(110111-1416133) F&U CREDIT INFORMATION CO.,
LTD.(135311-0003300) SK WYVERNS CO., LTD(120111-0217366) SK HOLDINGS CO., LTD.(110111-0022816) SK ENGINEERING & CONSTRUCTION CO.,
LTD.(110111-0038805) SK TELESYS CO., LTD.(110111-1405897) LOEN ENTERTAINMENT, INC.(134111-0010706) INFOSEC CO., LTD(110111-2007858) INDEPENDENCE CO., LTD.(110111-2010116) SKC MEDIA CO., LTD.(161511-0076377) IFILM CORPORATION(110111-2857451) SK BROADBAND CO., LTD.(110111-1466659) CU MEDIA. INC.(110111-2031477) NTREEV SOFT CO., LTD.(110111-2906456) SK I-MEDIA CO., LTD.(110111-3505851) IPLATFORM, INC(110111-3638917) NURI SOLUTION CO., LTD.(110111-1866213) HANAROMEDIA INC.(110111-3292664) HANARO DREAM INCORPORATED(110111-2183343) BROADBAND D&M CO., LTD.(110111-1509269) NOWON JOEUN TELECOM CO.,
LTD.(110111-3655218) MIRACLE INFORMATION & TELECOMMUNICATION
CO., LTD.(120111-0433491) ENCAR NETWORKS LTD.(110111-2125270) SK MARKETING & COMPANY CO., LTD.(110111-3874066) |
Not Available.
Not Available.
------
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.65.25 |
|
|
1 |
Rs.99.53 |
|
Euro |
1 |
Rs.73.47sss |
INFORMATION DETAILS
|
Analysis Done by
: |
KAR |
|
|
|
|
Report Prepared
by : |
TPT |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
|
-- |
NB |
New Business |
-- |
|
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major sections
of this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.